NHS breast cancer screening misses 95% of at-risk women under 50

The NHS is missing nearly all of the younger women most likely to develop breast cancer. Researchers from Cambridge University and the Institute of Cancer Research have found that current screening guidelines are so narrow they catch only a fraction of at-risk women under 50—and they're calling for a fundamental rethink of how the health service identifies who needs closer monitoring.

The problem is straightforward: the National Institute of Health and Care Excellence, which sets NHS policy, focuses almost exclusively on family history. If you're under 50 and don't have a strong genetic link to breast cancer in your relatives, the NHS doesn't screen you at all. Older women get routine mammograms. Younger women get nothing, unless they tick a very specific box. The researchers found this approach misses up to 95 percent of younger women who are actually at elevated risk.

Why does this matter? Breast cancer is a leading cause of death in women under 50 in the UK. About one in seven women will develop it at some point in their lives. Yet the current guidelines are built on a misconception: that most breast cancer is genetic. In reality, only 5 to 10 percent of cases are linked to inherited genes. The vast majority—96 percent of all breast cancer cases—occur in women over 40, and most of those women have no family history at all. Three-quarters of women under 50 who develop breast cancer within a decade have no family history whatsoever. They fall through the gap entirely.

The Cambridge team studied a different approach using a risk calculator called Boadicea, which weighs multiple factors: family history, yes, but also lifestyle choices, reproductive history, and genetic information. If the NHS used this tool to assess all women under 50, the researchers estimate that about a quarter would be flagged as at above-average risk and referred for further evaluation. More importantly, this would catch roughly a third of the women under 50 who actually develop breast cancer within ten years. Compare that to the current system, which refers just 1.4 percent of women under 50 and catches only 4.4 percent of those who will get the disease.

The gap is not a small oversight. It is a structural failure. The current guidelines would identify fewer than 5 in 100 at-risk younger women. The new approach would identify more than 25 in 100. The difference is the difference between catching a disease early and missing it entirely.

But there is a tension here that the researchers acknowledge openly. Expanding screening means more referrals, more appointments, more use of NHS resources that are already stretched. It also means more women will be told they are at higher risk, which can cause anxiety even if nothing develops. Dr. Juliet Usher-Smith, the lead researcher, said the NHS should review its criteria in light of these findings but recognized the practical complications. Cancer Research UK, which funded the work, emphasized that any changes must be equitable and must account for the worry that extra referrals might create.

Nice, the body that sets the guidelines, said it welcomes the research and recognizes the potential of multifactorial risk tools. But it stopped short of recommending a change, saying the current evidence does not yet warrant overhauling the system. The NHS breast cancer screening programme is regularly evaluated by the UK National Screening Committee, so the conversation is ongoing. For now, the guidance remains: all women should know what their breasts normally look and feel like, and should see a doctor if they notice any changes. It is a reasonable instruction. It is also, the researchers suggest, not nearly enough.